Janux Therapeutics Inc's ROI from its third quarter of 2026 to the third quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Janux Therapeutics Inc's ROI in the third quarter of 2026?
Janux Therapeutics Inc recorded a cumulative net loss of $-100 million during 12 months ending in the third quarter of 2026, resulting in a negative return on investment (ROI) of -10.45%.

Within the Healthcare sector 256 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the second quarter of 2026 from 1939 to 3148.

Definition and Formula of Return on Investment

Select the Comparisons :

None ▼

Select the Ratio:

Return on Investment ROI▼

None ▼

Return on Investment ROI▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Investment	(Sep 30 2026) III. Quarter	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter
Y / Y Investment Change TTM	-6.42 %	3.3 %	15.1 %	30.44 %	69.97 %
Y / Y Net Income Change TTM	-	-	-	-	-
Investment (TTM) in Millions	929	948	969	977	997
Return On Investment (TTM)	-10.45 %	-10.55 %	-11.58 %	-11.31 %	-9.98 %
JANX's Overall Ranking	# 3148	# 1939	# 2329	# 2886	#
Seq. Investment Change TTM	-1.74 %	-1.6 %	-1.59 %	-1.65 %	8.47 %
Seq. Net Income Change TTM	-	-	-	-	-
Net Income (TTM) in Millions	-100	-103	-114	-114	-102

JANX Company Profile >> Back to JANX Roi Comparisons >> See Annual JANX Return On Investment

Return On Investment JANX's Ranking
Within:	No.
Industry	# 88
Sector	# 257
Overall	# 3148

Return On Investment Statistics
High	Average	Low
-3.6 %	-11.57 %	-19.81 %
(Mar 31 2022)		(Jun 30 2023)

Financial Statements
Janux Therapeutics Inc's III. Quarter Investments	$ 929 Millions	JANX's Balance sheet
Janux Therapeutics Inc's III. Quarter Income	$ -22 Millions	Quarterly JANX's Income Statement
JANX's Income by Division		See JANX's Income by Division

JANX Annual Return On Investment	(Dec 31 2025) 2025	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022	(Dec 31 2021) 2021
Total Investments in Millions	977	1,044	367	348	367
Y / Y Investment Growth	-6.46 %	184.19 %	5.72 %	-5.32 %	-
Net Income in Millions	-114	-69	-58	-63	-33
Y / Y Net Income Growth	-	-	-	-	-
Annual Return On Investment	-11.64 %	-6.61 %	-15.87 %	-18.15 %	-8.9 %

Annual Roi Comment

Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
JANX's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for JANX's Competitors
Subscribers only: Roi for Janux Therapeutics Inc's Suppliers
Subscribers only: Return On Investment for JANX's Customers

Other Ratios
JANX's Roa	JANX's Inventory Turnover Ratio	JANX's Growth Rates	JANX's Dividend Statistics
	JANX's Profitability Ratios	JANX's Asset Turnover Ratio	JANX's Dividend Growth
JANX's Roe	JANX's Valuation Ratios	JANX's Financial Strength Ratios	JANX's Dividend Payout Ratio

Companies with similar Return On Investment at Sep 30 2026, within Healthcare Sector

ROI

Date modified: 2026-11-06T10:21:50+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.